PF 4965842

Drug Profile

PF 4965842

Alternative Names: PF 04965842; PF-4965842

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Discontinued Lupus vulgaris; Plaque psoriasis

Most Recent Events

  • 10 Jul 2018 Phase-III clinical trials in Atopic dermatitis (In adolescents, In adults, In children, In the elderly) in Germany, Canada and USA (PO) (NCT03349060)
  • 06 Jul 2018 Pfizer plans a phase III trial for Atopic dermatitis (In adolescents, In adults, In elderly) in Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czech Republic, Germany, Israel, Italy, Latvia, Mexico, Multinational, Netherlands, Poland, Russia, Serbia, Slovakia, Spain, Taiwan and USA (PO) (EudraCT2018-000501-23)
  • 29 Jun 2018 Pfizer plans the phase III JADE Mono-2 trial for Atopic dermatitis (In children, In adults, In adolescents, In the elderly) (NCT03575871) (EudraCT2018-001136-21)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top